AMGN Stock UPDATES Amgen Inc (AMGN) 162.18 11/02/2014 19:17:
Post# of 273249
Posted On: 11/02/2014 8:17:38 PM
Amgen Inc (AMGN) 162.18 $AMGN
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 45.18 (-1.03), PFE: 29.95 (+0.11), AMGN: 162.18 (+0.60), NVS: 92.69 (+0.74)
Final Glance: Biotechnology companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
The Untouchables: Where Even Activist Investors Fear to Tread
at The Street - Fri Oct 31, 1:58PM CDT
Up to now, companies in highly regulated industries were safe from activists.
AT: 2.22 (-0.01), ETR: 84.02 (-0.22), ACT: 242.74 (-0.47), CBRL: 115.35 (+0.35), EXC: 36.59 (-0.11), ITC: 39.61 (+0.11), AOL: 43.53 (+0.61), DYN: 30.50 (+0.88), AMGN: 162.18 (+0.60), AAPL: 108.00 (+1.02)
Midday Glance: Biotechnology companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)
Early Glance: Biotechnology companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
Aegerion Q3 Loss Wider than Expected, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 10:32AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) reported third-quarter 2014 net loss per share of 20 cents, wider than the Zacks Consensus Estimate of a loss of 18 cents.
AMGN: 162.18 (+0.60), AEGR: 20.19 (-14.02), SNY: 46.24 (+0.54), REGN: 393.72 (+0.92)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 321.08 (+0.08), BBH: 115.77 (-0.08), AMGN: 162.18 (+0.60), CELGZ: 3.61 (+0.06)
Next Resistance Level for Amgen (AMGN) is $161.31
Comtex SmarTrend(R) - Thu Oct 30, 12:26PM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $158.50 today and have reached the first resistance level of $160.10. Investors may be interested in a cross of the next upside pivot targets of $161.31 and $164.12.
AMGN: 162.18 (+0.60)
Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices
M2 - Thu Oct 30, 10:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szzlz3/biosimilars) has announced the addition of the "Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices" report to their offering. In this report, biopharmaceutical manufacturer decision-makers share their perspectives on: - Expected outsourcing of commercial biosimilar manufacturing - Comfort level with outsourcing to individual CMOs - Market trends and biosimilar manufacturing method preferences HOW YOU CAN USE THIS REPORT: Manufacturers - Stay on top of industry trends by learning what biopharmaceutical companies currently manufacturing large molecules think the future holds for biosimilar manufacturing - Learn what methods of biosimilar manufacturing peers are gravitating towards - Understand where, geographically, biopharmaceutical companies are looking to manufacturer biosimilars CMOs - Start to understand the market potential for outsourced biosimilar manufacturing - Learn what biopharmaceutical companies would value from a CMO and leverage these drivers in your sales and marketing efforts - Get an early indication of market leaders by knowing which manufacturers and CMOs respondents would be most comfortable using for biosimilar production Key Topics Covered: 1. Copyright and Usage Guidelines 2. Introduction 3. Methodology 4. Summary Respondent Demographics 5. Study Data 6. Respondent Demographics Companies Mentioned - Aenova - Amgen - Biogen Idec - Boehringer-Ingelheim GmbH - Cambridge Major - Catalent - Cedarburg Hauser Pharmaceuticals - Corden Pharma - DPT - Dr. Reddy's - DSM - Evonik - Famar - Fareva Holding - Haupt Pharma - Hospira - Jubilant Life Sciences - Lonza - LTS - Mylan - NextPharma - NIPRO - Patheon - Pfizer Global Supply - Piramal Healthcare Ltd - Recipharm - Roche/ Genentech - Sandoz - Teva - Therapure Biopharma For more information visit http://www.researchandmarkets.com/research/sz...iosimilars
BIIB: 321.08 (+0.08), AMGN: 162.18 (+0.60)
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire
PR Newswire - Thu Oct 30, 8:15AM CDT
Today, Analysts Review released its research reports regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Shire PLC (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7560-100free.
JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), AMGN: 162.18 (+0.60)
Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Oct 30, 8:00AM CDT
After some solid biotech stock earnings, these top ranked health care ETFs could be intriguing buys.
BIIB: 321.08 (+0.08), XBI: 171.39 (-1.98), BBH: 115.77 (-0.08), AMGN: 162.18 (+0.60)
Stocks Trim Losses After Fed Report; Solarwinds Soars
at Investor's Business Daily - Wed Oct 29, 3:22PM CDT
Stocks trimmed losses but couldn't avoid a heavy volume decline Wednesday. The Nasdaq fell 0.3%, the S&P 500 dropped 0.2% and the Dow Jones industrial average fell 0.1%. Preliminary numbers showed volume was higher across the board in the stock...
SWI: 47.55 (-0.04), AFSI: 44.87 (+0.76), AMGN: 162.18 (+0.60), SCOR: 42.14 (+0.39)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 321.08 (+0.08), LGND: 55.27 (+0.90), AMGN: 162.18 (+0.60), GSK: 45.49 (+0.35)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 321.08 (+0.08), CBST: 72.29 (-0.21), MDCO: 25.32 (-0.34), SRPT: 16.17 (+0.44), ALXN: 191.36 (-1.57), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 45.18 (-1.03), PFE: 29.95 (+0.11), AMGN: 162.18 (+0.60), NVS: 92.69 (+0.74)
Final Glance: Biotechnology companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
The Untouchables: Where Even Activist Investors Fear to Tread
at The Street - Fri Oct 31, 1:58PM CDT
Up to now, companies in highly regulated industries were safe from activists.
AT: 2.22 (-0.01), ETR: 84.02 (-0.22), ACT: 242.74 (-0.47), CBRL: 115.35 (+0.35), EXC: 36.59 (-0.11), ITC: 39.61 (+0.11), AOL: 43.53 (+0.61), DYN: 30.50 (+0.88), AMGN: 162.18 (+0.60), AAPL: 108.00 (+1.02)
Midday Glance: Biotechnology companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)
Early Glance: Biotechnology companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
Aegerion Q3 Loss Wider than Expected, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 10:32AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) reported third-quarter 2014 net loss per share of 20 cents, wider than the Zacks Consensus Estimate of a loss of 18 cents.
AMGN: 162.18 (+0.60), AEGR: 20.19 (-14.02), SNY: 46.24 (+0.54), REGN: 393.72 (+0.92)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 321.08 (+0.08), BBH: 115.77 (-0.08), AMGN: 162.18 (+0.60), CELGZ: 3.61 (+0.06)
Next Resistance Level for Amgen (AMGN) is $161.31
Comtex SmarTrend(R) - Thu Oct 30, 12:26PM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $158.50 today and have reached the first resistance level of $160.10. Investors may be interested in a cross of the next upside pivot targets of $161.31 and $164.12.
AMGN: 162.18 (+0.60)
Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices
M2 - Thu Oct 30, 10:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szzlz3/biosimilars) has announced the addition of the "Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices" report to their offering. In this report, biopharmaceutical manufacturer decision-makers share their perspectives on: - Expected outsourcing of commercial biosimilar manufacturing - Comfort level with outsourcing to individual CMOs - Market trends and biosimilar manufacturing method preferences HOW YOU CAN USE THIS REPORT: Manufacturers - Stay on top of industry trends by learning what biopharmaceutical companies currently manufacturing large molecules think the future holds for biosimilar manufacturing - Learn what methods of biosimilar manufacturing peers are gravitating towards - Understand where, geographically, biopharmaceutical companies are looking to manufacturer biosimilars CMOs - Start to understand the market potential for outsourced biosimilar manufacturing - Learn what biopharmaceutical companies would value from a CMO and leverage these drivers in your sales and marketing efforts - Get an early indication of market leaders by knowing which manufacturers and CMOs respondents would be most comfortable using for biosimilar production Key Topics Covered: 1. Copyright and Usage Guidelines 2. Introduction 3. Methodology 4. Summary Respondent Demographics 5. Study Data 6. Respondent Demographics Companies Mentioned - Aenova - Amgen - Biogen Idec - Boehringer-Ingelheim GmbH - Cambridge Major - Catalent - Cedarburg Hauser Pharmaceuticals - Corden Pharma - DPT - Dr. Reddy's - DSM - Evonik - Famar - Fareva Holding - Haupt Pharma - Hospira - Jubilant Life Sciences - Lonza - LTS - Mylan - NextPharma - NIPRO - Patheon - Pfizer Global Supply - Piramal Healthcare Ltd - Recipharm - Roche/ Genentech - Sandoz - Teva - Therapure Biopharma For more information visit http://www.researchandmarkets.com/research/sz...iosimilars
BIIB: 321.08 (+0.08), AMGN: 162.18 (+0.60)
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire
PR Newswire - Thu Oct 30, 8:15AM CDT
Today, Analysts Review released its research reports regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Shire PLC (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7560-100free.
JNJ: 107.78 (+0.74), MDT: 68.16 (+0.73), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), AMGN: 162.18 (+0.60)
Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Oct 30, 8:00AM CDT
After some solid biotech stock earnings, these top ranked health care ETFs could be intriguing buys.
BIIB: 321.08 (+0.08), XBI: 171.39 (-1.98), BBH: 115.77 (-0.08), AMGN: 162.18 (+0.60)
Stocks Trim Losses After Fed Report; Solarwinds Soars
at Investor's Business Daily - Wed Oct 29, 3:22PM CDT
Stocks trimmed losses but couldn't avoid a heavy volume decline Wednesday. The Nasdaq fell 0.3%, the S&P 500 dropped 0.2% and the Dow Jones industrial average fell 0.1%. Preliminary numbers showed volume was higher across the board in the stock...
SWI: 47.55 (-0.04), AFSI: 44.87 (+0.76), AMGN: 162.18 (+0.60), SCOR: 42.14 (+0.39)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 321.08 (+0.08), LGND: 55.27 (+0.90), AMGN: 162.18 (+0.60), GSK: 45.49 (+0.35)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 321.08 (+0.08), CBST: 72.29 (-0.21), MDCO: 25.32 (-0.34), SRPT: 16.17 (+0.44), ALXN: 191.36 (-1.57), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
(0)
(0)Scroll down for more posts ▼